Application Note: Efficient Gene Editing of iPSCs
CellFE releases a cGMP-compatible workflow to support highly efficient gene editing of iPSCs via a non-viral approach for cell therapy manufacturing.
CellFE releases a cGMP-compatible workflow to support highly efficient gene editing of iPSCs via a non-viral approach for cell therapy manufacturing.
CellFE® today announced the launch of its highly anticipated CellFE T-Rest™, a first-in-class cell manufacturing transfection media product designed specifically for resting T cell workflows, along with an app note.
CellFE Appoints Mike Rice to Board of Directors
CellFE announced today an upcoming presentation by CEO Alla Zamarayeva, PhD, at the International Society of Gene & Cell Therapy (ISCT) Annual Meeting, taking place May 29-June 1, 2024 in Vancouver, BC.
CellFE announced today an upcoming presentation by CSO Todd Sulchek, PhD, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 7-11, 2024 in Baltimore, MD.
CellFE announced the completion of a $22 million Series A financing led by M Ventures, with participation from Great Point Ventures, Riverine Ventures and its existing investors.
CellFE announced it has raised $3.6 million in an initial Series Seed, co-led by Cota Capital and Dynamk Capital, and joined by Embark Ventures.